Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26), taking place in London from 13–16 March 2026.

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Shun Zhang discussing a phase 1 study of QLH12016, an androgen receptor PROTAC degrader in ...

TWO NEW CLINICAL trials at The Miriam Hospital are focused on prostate cancer treatments designed to precisely target prostate cancer cells while minimizing damage to healthy tissue. / COURTESY THE ...

LOS ANGELES (KABC) -- A cancer patient says the ongoing strike by Kaiser Permanente workers has disrupted his chemotherapy treatments, leaving him worried about delays. Tom Bicknell, who is living ...

When James Choate-Deeds was diagnosed with prostate cancer, he joined a clinical trial for robotic-assisted surgery Wendy Grossman Kantor is an award-winning journalist who has contributed to PEOPLE ...

Judy McNair has spent more than 20 years in treatment for cancer. During regular infusions at the WVU Cancer Institute’s Mary Babb Randolph Cancer Center, she often speaks about the support she has ...

Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine. If you watched the Super Bowl, you ...